The RNS is all very vague. I think investors and the market want to see names that are going to directly impact on this firms finances and still none have been named.
Just had a shiver down my spine...this feels like a co ordinated ramp. I'd have the Fear of buying in at this price... Just sayin.....but what do I know,
Dr Christopher Chiu, from the department of infectious disease at Imperial College London is leading a study designed to asses the viability of inhled formulations .